KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $6.2 million.

  • Twist Bioscience's Depreciation & Amortization (CF) fell 291.54% to $6.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $24.7 million, marking a year-over-year decrease of 1678.08%. This contributed to the annual value of $24.9 million for FY2025, which is 2093.09% down from last year.
  • Latest data reveals that Twist Bioscience reported Depreciation & Amortization (CF) of $6.2 million as of Q4 2025, which was down 291.54% from $6.0 million recorded in Q3 2025.
  • Over the past 5 years, Twist Bioscience's Depreciation & Amortization (CF) peaked at $8.5 million during Q3 2023, and registered a low of $2.5 million during Q1 2021.
  • In the last 5 years, Twist Bioscience's Depreciation & Amortization (CF) had a median value of $6.1 million in 2025 and averaged $5.8 million.
  • As far as peak fluctuations go, Twist Bioscience's Depreciation & Amortization (CF) surged by 9959.69% in 2022, and later tumbled by 2693.65% in 2025.
  • Twist Bioscience's Depreciation & Amortization (CF) (Quarter) stood at $3.2 million in 2021, then skyrocketed by 68.0% to $5.3 million in 2022, then soared by 54.4% to $8.2 million in 2023, then dropped by 21.92% to $6.4 million in 2024, then fell by 2.92% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q4 2025, $6.0 million for Q3 2025, and $6.1 million during Q2 2025.